U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Kidney Medullary Carcinoma

MedGen UID:
1695151
•Concept ID:
C5206775
•
Neoplastic Process

Definition

A kidney medullary carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Kidney Medullary Carcinoma

Professional guidelines

PubMed

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S, Wang H
Drug Des Devel Ther 2023;17:3429-3437. Epub 2023 Nov 15 doi: 10.2147/DDDT.S426898. PMID: 38024530Free PMC Article
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM
Clin Genitourin Cancer 2019 Feb;17(1):1-6. Epub 2018 Sep 12 doi: 10.1016/j.clgc.2018.09.005. PMID: 30287223Free PMC Article
Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma.
Sarlis NJ, Gourgiotis L
Curr Drug Targets Immune Endocr Metabol Disord 2004 Sep;4(3):187-98. doi: 10.2174/1568008043339866. PMID: 15379722

Recent clinical studies

Etiology

SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G
Proc Natl Acad Sci U S A 2023 May 23;120(21):e2209639120. Epub 2023 May 15 doi: 10.1073/pnas.2209639120. PMID: 37186844Free PMC Article
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P
Clin Genitourin Cancer 2021 Dec;19(6):e401-e408. Epub 2021 Sep 15 doi: 10.1016/j.clgc.2021.08.007. PMID: 34625389

Diagnosis

SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G
Proc Natl Acad Sci U S A 2023 May 23;120(21):e2209639120. Epub 2023 May 15 doi: 10.1073/pnas.2209639120. PMID: 37186844Free PMC Article
Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S, Koch CA, Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne) 2022;13:896287. Epub 2022 May 30 doi: 10.3389/fendo.2022.896287. PMID: 35712243Free PMC Article
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P
Clin Genitourin Cancer 2021 Dec;19(6):e401-e408. Epub 2021 Sep 15 doi: 10.1016/j.clgc.2021.08.007. PMID: 34625389
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM
Clin Genitourin Cancer 2019 Feb;17(1):1-6. Epub 2018 Sep 12 doi: 10.1016/j.clgc.2018.09.005. PMID: 30287223Free PMC Article
Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma.
Pirich LM, Chou P, Walterhouse DO
J Pediatr Hematol Oncol 1999 Jan-Feb;21(1):67-9. PMID: 10029817

Therapy

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S, Wang H
Drug Des Devel Ther 2023;17:3429-3437. Epub 2023 Nov 15 doi: 10.2147/DDDT.S426898. PMID: 38024530Free PMC Article
Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S, Koch CA, Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne) 2022;13:896287. Epub 2022 May 30 doi: 10.3389/fendo.2022.896287. PMID: 35712243Free PMC Article
Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P
Clin Genitourin Cancer 2021 Dec;19(6):e401-e408. Epub 2021 Sep 15 doi: 10.1016/j.clgc.2021.08.007. PMID: 34625389
Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM
Clin Genitourin Cancer 2019 Feb;17(1):1-6. Epub 2018 Sep 12 doi: 10.1016/j.clgc.2018.09.005. PMID: 30287223Free PMC Article
Sunitinib: from rational design to clinical efficacy.
Chow LQ, Eckhardt SG
J Clin Oncol 2007 Mar 1;25(7):884-96. doi: 10.1200/JCO.2006.06.3602. PMID: 17327610

Prognosis

Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM
Clin Genitourin Cancer 2019 Feb;17(1):1-6. Epub 2018 Sep 12 doi: 10.1016/j.clgc.2018.09.005. PMID: 30287223Free PMC Article
Discovery of a renal medullary carcinoma in an adolescent male with sickle cell trait by Tc-99m methylene disphosponate bone scintigraphy.
Brown JM, Berkey BD, Brooks JA
Clin Nucl Med 2008 Dec;33(12):896-900. doi: 10.1097/RLU.0b013e31818bf31d. PMID: 19033803
Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma.
Pirich LM, Chou P, Walterhouse DO
J Pediatr Hematol Oncol 1999 Jan-Feb;21(1):67-9. PMID: 10029817

Clinical prediction guides

SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G
Proc Natl Acad Sci U S A 2023 May 23;120(21):e2209639120. Epub 2023 May 15 doi: 10.1073/pnas.2209639120. PMID: 37186844Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...